Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607) , a leading pharmaceutical company based in China, has entered into a comprehensive partnership with the French pharmaceutical giant Sanofi (NASDAQ: SNY). The collaboration aims to address major disease areas on a nationwide scale, establishing an end-to-end value chain system that spans from import and distribution to end sales. While the financial specifics of the agreement have not been disclosed, the partnership signals a significant expansion of their long-standing cooperation in China.
The broad scope of their collaboration will encompass key therapeutic areas such as cardiovascular diseases, central nervous system diseases, and oncology. This partnership is expected to leverage the strengths of both companies to improve access to and the quality of healthcare services across China.- Flcube.com
